1. Home
  2. ACRS vs TAYD Comparison

ACRS vs TAYD Comparison

Compare ACRS & TAYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$5.53

Market Cap

868.5M

Sector

Health Care

ML Signal

HOLD

Logo Taylor Devices Inc.

TAYD

Taylor Devices Inc.

N/A

Current Price

$59.33

Market Cap

165.2M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
ACRS
TAYD
Founded
2012
1955
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
868.5M
165.2M
IPO Year
2015
1995

Fundamental Metrics

Financial Performance
Metric
ACRS
TAYD
Price
$5.53
$59.33
Analyst Decision
Strong Buy
Hold
Analyst Count
5
1
Target Price
$10.20
$70.00
AVG Volume (30 Days)
1.9M
39.0K
Earning Date
05-07-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
69.01
N/A
EPS
N/A
2.62
Revenue
$1,683,000.00
$41,649,673.00
Revenue This Year
N/A
$0.25
Revenue Next Year
$4.24
$19.78
P/E Ratio
N/A
$22.89
Revenue Growth
N/A
N/A
52 Week Low
$1.74
$40.50
52 Week High
$6.60
$90.37

Technical Indicators

Market Signals
Indicator
ACRS
TAYD
Relative Strength Index (RSI) 45.15 52.78
Support Level $4.13 $57.54
Resistance Level $5.87 $59.13
Average True Range (ATR) 0.34 1.78
MACD -0.11 -0.22
Stochastic Oscillator 32.87 20.51

Price Performance

Historical Comparison
ACRS
TAYD

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

About TAYD Taylor Devices Inc.

Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.

Share on Social Networks: